Physician profile
Ernest Opoku Asamoah
NPI 1427079672
$959,330.60
in general payments reported to CMS, 2019-2025
66 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170K · 2020: $108K · 2021: $146K · 2022: $127K · 2023: $139K · 2024: $130K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $289K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $44K · Travel and Lodging: $38K · Food and Beverage: $24K · Honoraria: $7,265 · Consulting Fee: $5,685 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $289,408.13 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $44,428.50 |
| Travel and Lodging | $37,897.90 |
| Food and Beverage | $24,034.46 |
| Honoraria | $7,265.00 |
| Consulting Fee | $5,685.00 |
| Education | $113.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $361,600.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $130,395.48 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $80,307.03 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $71,969.65 | 2019-2024 | Farxiga |
| Amgen INC. | $59,974.88 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $49,517.71 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Alexion Pharmaceuticals, INC. | $43,274.90 | 2019-2025 | Strensiq |
| Mannkind Corporation | $41,304.35 | 2019-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33,485.33 | 2019-2025 | Jardiance |
| Radius Health, INC. | $17,739.27 | 2019-2025 | Tymlos |
| Ibsa Pharma INC. | $15,531.46 | 2019-2025 | Tirosint, Licart, Flector |
| Abbvie INC. | $14,082.61 | 2019-2025 | Synthroid, Botox |
| Horizon Therapeutics Plc | $9,797.62 | 2019-2023 | Tepezza |
| Esperion Therapeutics, INC. | $6,680.88 | 2020-2024 | Nexletol |
| Chiesi USA, INC. | $6,511.27 | 2025 | Mycapssa |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,558.36 | 2019 | |
| Vistapharm, INC. | $2,750.00 | 2021 | |
| Medtronic, INC. | $1,872.42 | 2022-2025 | Minimed 780g, Intellis Adaptivestim, Minimed 770g |
| Corcept Therapeutics | $1,232.56 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $591.42 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $534.34 | 2019-2025 | Unithroid |
| Beta Bionics, INC. | $394.91 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $391.66 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $377.66 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $333.35 | 2023-2025 | |
| Antares Pharma, INC. | $332.52 | 2019-2024 | Xyosted |
| Kyowa Kirin, INC. | $269.26 | 2023-2025 | Crysvita |
| Insulet Corporation | $265.27 | 2022-2025 | Omnipod |
| Pfizer INC. | $255.67 | 2020-2025 | |
| Amarin Pharma, INC. | $237.33 | 2019-2022 | |
| Sequel Med Tech, LLC | $225.07 | 2025 | Twiist |
| Merck Sharp & Dohme LLC | $207.14 | 2019-2022 | |
| Astellas Pharma US INC | $156.45 | 2024-2025 | Veozah |
| Recordati_rare_diseases_inc. | $147.24 | 2022-2025 | Isturisa |
| Companion Medical, INC. | $143.83 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $141.94 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $135.18 | 2023-2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $123.74 | 2025 | |
| Madrigal Pharmaceuticals | $102.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Shire North American Group INC | $101.21 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $94.63 | 2019-2024 | Crysvita |
| Lifescan, INC. | $91.55 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $89.69 | 2019-2022 | |
| Eisai INC. | $80.95 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $78.74 | 2020 | |
| Vivus LLC | $76.95 | 2019-2022 | |
| Cequr Corporation | $70.11 | 2023-2024 | Cequr Simplicity |
| Medtronic Minimed, INC. | $60.60 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $59.92 | 2019-2023 | Livalo, Seglentis |
| Averitas Pharma INC. | $55.52 | 2023-2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.97 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $52.43 | 2023 | Onpattro |
| Almatica Pharma LLC | $50.19 | 2024 | Teriparatide |
| Soleno Therapeutics, INC. | $48.37 | 2025 | Vykat Xr |
| Senseonics, Incorporated | $36.00 | 2019 | |
| Amryt Pharma Holdings Ltd | $34.84 | 2023 | Mycapssa |
| Verity Pharmaceuticals INC. | $34.36 | 2024 | Tlando |
| Ascensia Diabetes Care US INC. | $33.88 | 2024 | |
| Halozyme INC | $33.11 | 2023 | |
| Glaxosmithkline, LLC. | $31.54 | 2025 | Shingrix, Arexvy |
| Acella Pharmaceuticals, LLC | $30.58 | 2023-2025 | NP Thyroid 60 |
| Takeda Pharmaceuticals U.S.A., INC. | $25.17 | 2020 | |
| Eusa Pharma (US) LLC | $19.96 | 2022 | |
| Currax Pharmaceuticals LLC | $19.76 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $11.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $2.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Asamoah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.